Kinarus Therapeutics

📍 Basel, Switzerland🗓 Founded 2017👥 11 employees💰 Last funded Sep 2017

Kinarus Therapeutics (SIX:KNRS) is a clinical-stage pharmaceutical company focused on bringing novel, patient-focused treatments for viral, respiratory, and ophthalmic diseases. Kinarus was incorporated in Basel, Switzerland in 2017. Our lead drug candidate is an oral combination of a clinical-stage P38 mitogen activated protein kinase (p38 MAPK) inhibitor, in-licensed from Roche, and a second drug, together enabling an oral, long-term effective treatment. Kinarus has launched a large Phase 2 clinical trial in hospitalized Covid-19 patients with the aim to reduce mortality and duration of hospital stay. The mechanism of action of our candidate is three-fold; reducing viral replication, inflammation, and organ damage. The trial is actively enrolling patients. Kinarus has also obtained regulatory approval for a one-year Phase 2 clinical trial in patients diagnosed with wet Age-Related Macular Degeneration. Injectable agents targeting vascular endothelial growth factor are the only approved therapies. Despite the availability of these drugs, real-world data shows significant under-treatment leading to progressive loss of vision and blindness. Kinaruss drug candidate, administered on top of anti-VEGF agents, has the potential to reduce injection frequency, providing additional therapeutic benefit and relieving the high burden to patients and their caregivers.

Total investors

Early stage

Mid stage

Late stage

2017

Founded